查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1691770

抗結核病治療市場 - 全球行業規模、佔有率、趨勢、機會和預測，按疾病類型、按診斷和治療（診斷、治療、其他）、按最終用戶、按地區和競爭進行細分，2020-2030 年

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Diagnosis and Treatment (Diagnosis, Treatment, others), By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球抗結核治療市場價值為 13.205 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 5.90%。抗結核 (TB) 治療是指用於管理和治療結核病的藥物和治療策略，結核病是一種主要由結核分枝桿菌引起的細菌感染。結核病是一種傳染病，主要影響肺部，但也會影響身體的其他器官和系統。有效的抗結核病治療對於控制結核病的傳播和預防其併發症至關重要。藥物敏感型結核病的標準治療方案通常是每天服用多種第一線藥物，持續六至九個月。此持續時間可能因疾病的嚴重程度和患者對治療的反應等因素而異。抗藥性結核病的治療更加複雜，可能涉及二線藥物。治療方案永續 18 至 24 個月或更長時間，使用的特定藥物取決於結核病細菌的抗藥性模式。接受抗結核病治療的患者會受到定期監測，以評估其對治療的反應並發現任何副作用。監測包括臨床評估、實驗室測試和放射學檢查。

市場概況
預測期 2026-2030
2024 年市場規模 13.205億美元
2030 年市場規模 18.4748億美元
2025-2030 年複合年成長率 5.90％
成長最快的領域 活動性結核病
最大的市場 北美洲

主要市場促進因素

抗藥性結核菌的出現

主要市場挑戰

恥辱和社會決定因素

主要市場趨勢

治療方案簡化

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球抗結核治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病類型（活動性結核病、潛伏性結核病、其他）
    • 依診斷及治療（診斷（血液檢查、影像檢查、痰液檢查、其他）、治療（第一線藥物、第二線藥物、其他）、其他）
    • 按最終使用者（醫院、專科診所、家庭護理等）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：亞太地區抗結核治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章：歐洲抗結核治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美抗結核治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 9 章：南美洲抗結核病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲抗結核病治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球抗結核治療市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

  • AstraZeneca Plc
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 17353

Global Anti-Tuberculosis Therapeutics Market was valued at USD 1320.50 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.90% through 2030. Anti-tuberculosis (TB) therapeutics refer to the medications and treatment strategies used to manage and cure tuberculosis, a bacterial infection primarily caused by Mycobacterium tuberculosis. TB is a contagious disease that primarily affects the lungs but can also affect other organs and systems in the body. Effective anti-TB therapeutics are essential for controlling the spread of TB and preventing its complications. Standard treatment regimens for drug-susceptible TB typically involve a combination of first-line drugs taken daily for six to nine months. This duration may vary based on factors like the severity of the disease and the patient's response to treatment. Treatment for drug-resistant TB is more complex and may involve second-line drugs. Regimens can last for 18 to 24 months or longer, and the specific drugs used depend on the resistance pattern of the TB bacteria. Patients receiving anti-TB treatment are regularly monitored to assess their response to treatment and to detect any adverse effects. Monitoring includes clinical evaluations, laboratory tests, and radiological examinations.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1320.50 Million
Market Size 2030USD 1847.48 Million
CAGR 2025-20305.90%
Fastest Growing SegmentActive TB
Largest MarketNorth America

Key Market Drivers

Emergence of Drug-Resistant TB Strains

Drug-resistant TB occurs when the bacterium that causes TB, Mycobacterium tuberculosis, becomes resistant to one or more of the drugs commonly used to treat the disease. Multidrug-Resistant TB (MDR-TB) is defined as resistance to both isoniazid and rifampin, which are the two most potent first-line anti-TB drugs. MDR-TB is more challenging to treat than drug-susceptible TB because it requires a longer duration of treatment with second-line drugs, which are less effective and often have more side effects. Extensively Drug-Resistant TB (XDR-TB) is a more severe form of drug resistance and is defined as resistance to isoniazid and rifampin (MDR-TB) plus resistance to any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, kanamycin, or capreomycin). XDR-TB is even more challenging to treat and often requires highly toxic medications with limited efficacy.

One of the primary factors driving drug resistance is the incomplete or inadequate treatment of TB. When patients do not complete the full course of their prescribed TB medications or when the drugs are not administered correctly, it creates conditions that allow the TB bacteria to develop resistance to the drugs. The inappropriate use of antibiotics, including the use of TB drugs for non-TB infections or the use of low-quality or substandard medications, can contribute to drug resistance. Patients may fail to adhere to their TB treatment regimens for various reasons, such as experiencing side effects, stigma associated with TB, or challenges with accessing healthcare services.

Non-adherence can result in treatment failure and drug resistance. Drug-resistant TB strains can be transmitted from person to person. Close contact with an individual infected with a drug-resistant strain can lead to new cases of drug-resistant TB. Poor infection control measures in healthcare settings can facilitate the spread of drug-resistant TB strains, particularly in hospitals and clinics. In some regions, there may be limited access to second-line anti-TB drugs or diagnostic tools to detect drug resistance. This can delay the identification and appropriate treatment of drug-resistant cases. Individuals with compromised immune systems, such as those living with HIV, are at higher risk of developing drug-resistant TB due to their reduced ability to fight off the infection. This factor will help in the development of the Global Anti-Tuberculosis Therapeutics Market.

Key Market Challenges

Stigma and Social Determinants

TB has historically carried a social stigma due to its contagious nature. People with TB may face discrimination and social isolation, which can discourage them from seeking diagnosis and treatment. Individuals diagnosed with TB may internalize societal stigma, leading to feelings of shame and guilt. This self-stigma can negatively affect mental health and willingness to adhere to treatment. Stigma can lead to delays in seeking diagnosis and treatment. Individuals may avoid healthcare facilities out of fear of being stigmatized, leading to delayed diagnosis and worsening of their condition. Stigmatized individuals may be less likely to adhere to their TB treatment regimens, which can lead to treatment failure and the development of drug-resistant TB strains.

Social determinants such as poverty, homelessness, and limited access to healthcare are often linked to a higher risk of TB. Vulnerable populations face increased challenges in accessing diagnosis and treatment, exacerbating the impact of stigma. TB-HIV co-infected individuals often face compounded stigma and discrimination. Managing both diseases require specialized care and support. Reducing TB-related stigma requires education and awareness campaigns that address misconceptions and promote empathy and understanding. These initiatives are essential but require resources and sustained efforts.

Key Market Trends

Treatment Regimen Simplification

Traditional TB treatment regimens often involve multiple pills taken daily for several months. Simplified regimens aim to reduce the number of pills, making it easier for patients to adhere to their treatment plans. Fixed-Dose Combinations (FDCs) combine multiple anti-TB drugs into a single tablet, reducing the complexity of treatment. This approach simplifies dosing schedules and enhances patient adherence. Efforts are underway to develop shorter-duration treatment regimens for TB. For example, some clinical trials have explored the feasibility of shorter treatment courses, such as the 4-month regimen for rifampin-sensitive TB. Simplified regimens may involve fewer clinic visits for drug administration or monitoring. This is particularly important for patients who face challenges in accessing healthcare facilities.

Integrating TB treatment with other healthcare services, such as HIV care, maternal and child health, and non-communicable disease management, can simplify care for patients with multiple health needs. Developing pediatric-friendly formulations of anti-TB drugs, including child-appropriate FDCs and liquid formulations, simplifies treatment for children with TB. Mobile health (mHealth) technologies and digital tools can provide treatment reminders, track medication adherence, and support patients in adhering to their treatment regimens. Community health workers and TB treatment supporters can play a crucial role in simplifying treatment by delivering medications to patients in their communities and providing support. Improved diagnostics, such as molecular tests that rapidly detect TB and drug resistance, contribute to more precise treatment decisions and regimens.

Key Market Players

  • AstraZeneca Plc.
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Anti-Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Tuberculosis Therapeutics Market, By Disease Type:

  • Active TB
  • Latent TB
  • Others

Anti-Tuberculosis Therapeutics Market, By Diagnostic and Treatment:

  • Diagnosis
    • Blood Tests
    • Imaging Tests
    • Sputum Tests
    • Others
  • Treatment
    • First Line of Drug

O Isoniazid

O Ethambutol

O Rifampin

O Others

    • Second Line of Drugs

O Thiacetazone

O Paraaminosalicyclic Acid (PAS)

O Others

    • Others
  • Others

Anti-Tuberculosis Therapeutics Market, By End-User:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Anti-Tuberculosis Therapeutics Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anti-Tuberculosis Therapeutics Market.

Available Customizations:

Global Anti-Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Tuberculosis Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Active TB, Latent TB, Others)
    • 5.2.2. By Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others)
    • 5.2.3. By End User (Hospitals, Specialty Clinics, Homecare, others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Anti-Tuberculosis Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Diagnosis and Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Diagnosis and Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. India Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Diagnosis and Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Diagnosis and Treatment
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Diagnosis and Treatment
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Anti-Tuberculosis Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Diagnosis and Treatment
        • 6.3.5.2.3. By End User

7. Europe Anti-Tuberculosis Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Diagnosis and Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Diagnosis and Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Diagnosis and Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Diagnosis and Treatment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Diagnosis and Treatment
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Anti-Tuberculosis Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Diagnosis and Treatment
        • 7.3.5.2.3. By End User

8. North America Anti-Tuberculosis Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Diagnosis and Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Anti-Tuberculosis Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Diagnosis and Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Anti-Tuberculosis Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Diagnosis and Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Anti-Tuberculosis Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Diagnosis and Treatment
        • 8.3.3.2.3. By End User

9. South America Anti-Tuberculosis Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Diagnosis and Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Anti-Tuberculosis Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Diagnosis and Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Anti-Tuberculosis Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Diagnosis and Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Anti-Tuberculosis Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Diagnosis and Treatment
        • 9.3.3.2.3. By End User

10. Middle East and Africa Anti-Tuberculosis Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Diagnosis and Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Anti-Tuberculosis Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Diagnosis and Treatment
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Anti-Tuberculosis Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Diagnosis and Treatment
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Anti-Tuberculosis Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Diagnosis and Treatment
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Anti-Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. AstraZeneca Plc
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Johnson & Johnson Private Limited
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Eli Lilly and Company
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. F. Hoffmann-La Roche Ltd.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Mylan N.V.
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Teva Pharmaceutical Industries Ltd.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Sanofi SA
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Novartis AG
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Sun Pharmaceutical Industries Ltd.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Merck & Co., Inc.
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer